Secondary Central Nervous System Lymphoma Clinical Trials

6 recruiting

Secondary Central Nervous System Lymphoma Trials at a Glance

8 actively recruiting trials for secondary central nervous system lymphoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Middletown, Montvale, and Basking Ridge. Lead sponsors running secondary central nervous system lymphoma studies include Memorial Sloan Kettering Cancer Center, City of Hope Medical Center, and Beijing Boren Hospital.

Browse secondary central nervous system lymphoma trials by phase

Treatments under study

About Secondary Central Nervous System Lymphoma Clinical Trials

Looking for clinical trials for Secondary Central Nervous System Lymphoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Secondary Central Nervous System Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Secondary Central Nervous System Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma

Relapsed/Refractory Primary Central Nervous System LymphomaRelapsed/Refractory Central Nervous System LymphomaRelapsed/Refractory Secondary Central Nervous System Lymphoma
Beijing Boren Hospital30 enrolled1 locationNCT07555561
Recruiting
Phase 1

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Secondary Central Nervous System LymphomaPrimary Central Nervous System (CNS) Lymphoma
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT07137494
Recruiting
Phase 2

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Hematopoietic and Lymphoid Cell NeoplasmLymphomaLeukemia+3 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT05011045
Recruiting
Phase 1

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
City of Hope Medical Center20 enrolled1 locationNCT06922604
Recruiting
Phase 1Phase 2

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Primary Central Nervous System LymphomaSecondary Central Nervous System LymphomaCNS Lymphoma
James Rubenstein35 enrolled1 locationNCT05351593